Home » Stocks » Delcath Systems

Delcath Systems, Inc. (DCTH)

Stock Price: $9.87 USD 0.16 (1.65%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 34.70M
Revenue (ttm) 1.60M
Net Income (ttm) -8.85M
Shares Out 3.52M
EPS (ttm) -496.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $9.87
Previous Close $9.71
Change ($) 0.16
Change (%) 1.65%
Day's Open 9.64
Day's Range 9.55 - 10.05
Day's Volume 60,527
52-Week Range 5.15 - 14.00

More Stats

Market Cap 34.70M
Enterprise Value 32.67M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 3.52M
Float 2.50M
EPS (basic) -574.07
EPS (diluted) -496.64
FCF / Share -362.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 25,145
Short Ratio 0.20
Short % of Float 0.63%
Beta 0.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21.63
PB Ratio n/a
Revenue 1.60M
Operating Income -19.31M
Net Income -8.85M
Free Cash Flow -26.35M
Net Cash 2.03M
Net Cash / Share 0.58
Gross Margin 53.68%
Operating Margin -1,203.93%
Profit Margin -551.90%
FCF Margin -1,642.83%
ROA -151.41%
ROE n/a
ROIC 45.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(97.57% upside)
Current: 9.87
Target: 19.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-53.62%25.49%-
Gross Profit0.862.402.01
Operating Income-19.91-27.07-18.17
Net Income-8.88-19.22-45.12
Shares Outstanding0.030.04-
Earnings Per Share-1,047.00-504.00-2,275,000.00
Operating Cash Flow-23.69-14.73-15.40
Capital Expenditures-0.02-0.08-0.52
Free Cash Flow-23.71-14.81-15.92
Cash & Equivalents10.183.585.32
Total Debt2.862.04-
Net Cash / Debt7.321.545.32
Book Value-6.36-14.940.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Delcath Systems, Inc.
Country United States
Employees 33
CEO John Purpura

Stock Information

Ticker Symbol DCTH
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: DCTH


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.